New activities of homoyessotoxin against lung cancer through the regulation of EGFR/PI3K/AKT pathway

Abstract

Non-small cell lung cancer (NSCLC) remains a major cause of cancer-related mortality worldwide, emphasizing the need for novel therapeutic strategies. In this study, we demonstrate that homoyessotoxin (hYTXs), a marine-derived natural compound, exerts potent anti-NSCLC progression. Network pharmacology, molecular docking, molecular dynamics simulations, and SPR analysis confirmed a strong binding affinity between hYTXs and EGFR. Mechanistically, hYTXs disrupted EGFR trafficking by accelerating its endocytosis and enhancing its accumulation within lysosomes, thereby accelerating receptor degradation without altering EGFR mRNA levels. CHX chase and lysosomal inhibition assays further verified that hYTXs downregulated EGFR through post-translational regulation. This degradation led to suppression of downstream PI3K/AKT/ERK signaling, reduced phosphorylation of FOXO3a and p70S6K, and enhanced PTEN nuclear translocation. Functionally, hYTXs induced apoptosis, oxidative stress, S-phase arrest, mitochondrial dysfunction, and DNA damage in A549 cells, with comparable inhibitory potency in EGFR-mutant lines (PC9, H1975) but minimal cytotoxicity toward normal lung epithelial cells. In vivo, hYTXs significantly inhibited tumor growth and exhibited excellent safety based on serum biochemistry and lung histology. Collectively, hYTXs represents a promising next-generation EGFR-targeting compound that overcomes kinase-mutation-driven resistance by promoting receptor degradation rather than kinase inhibition.

Keywords

Homoyessotoxin / Non-small cell lung cancer / EGFR / Apoptosis / Network pharmacology / Proteomics

References

[1] Al-Akhrass H, Naves T, Vincent F, Magnaudeix A, Durand K, Bertin F, Melloni B, Jauberteau M-O, Lalloué F. Sortilin limits Egfr signaling by promoting its internalization in lung cancer. Nat Commun, 2017, 8 1182

[2] Alam M, Hasan GM, Eldin SM, Adnan M, Riaz MB, Islam A, Khan I, Hassan MI. Investigating regulated signaling pathways in therapeutic targeting of non-small cell lung carcinoma. Biomed Pharmacother, 2023, 161 114452

[3] Amin AR, Kucuk O, Khuri FR, Shin DM. Perspectives for cancer prevention with natural compounds. J Clin Oncol, 2009, 27: 2712-2725

[4] Balata H, Fong KM, Hendriks LE, Lam S, Ostroff JS, Peled N, Wu N, Aggarwal C. Prevention and early detection for Nsclc: advances in thoracic oncology 2018. J Thorac Oncol, 2019, 14: 1513-1527

[5] Bellacosa A, Kumar CC, Di Cristofano A, Testa JR. Activation of Akt kinases in cancer: implications for therapeutic targeting. Adv Cancer Res, 2005, 94: 29-86

[6] Brognard J, Dennis P. Variable apoptotic response of nsclc cells to inhibition of the mek/erk pathway by small molecules or dominant negative mutants. Cell Death Differ, 2002, 9: 893-904

[7] Du J, Li J, Gao M, Guan Q, Liu T, Wu Y, Li Z, Zuo D, Zhang W, Wu Y. May, a novel tubulin inhibitor, induces cell apoptosis in A549 and A549/Taxol cells and inhibits epithelial-mesenchymal transition in A549/Taxol cells. Chem Biol Interact, 2020, 323 109074

[8] Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale C-M, Zhao X, Christensen J. Met amplification leads to gefitinib resistance in lung cancer by activating Erbb3 signaling. Science, 2007, 316: 1039-1043

[9] Gao X, Wang H, Chen K, Guo Y, Zhou J, Xie W. Toxicological and pharmacological activities, and potential medical applications, of marine algal toxins. Int J Mol Sci, 2024

[10] Gao X, Chen K, Wang H, Guo Y, Zhang N, Su W, Zhou J, Xie W. Homoyessotoxin alleviates inflammatory responses by regulating the Tlr4/Myd88/Nfκb and Nrf2/Ho-1 pathways. Life Sci, 2025, 379 123858

[11] Garg R, Cooke M, Benavides F, Abba MC, Cicchini M, Feldser DM, Kazanietz MG. Pkcε is required for KRAS-driven lung tumorigenesis. Cancer Res, 2020, 80: 5166-5173

[12] He Y, Sun MM, Zhang GG, Yang J, Chen KS, Xu WW, Li B. Targeting Pi3k/Akt signal transduction for cancer therapy. Signal Transduct Target Ther, 2021, 6 425

[13] Heavey S, O’Byrne KJ, Gately K. Strategies for co-targeting the Pi3k/Akt/Mtor pathway in Nsclc. Cancer Treat Rev, 2014, 40: 445-456

[14] Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys, 2004, 59: 21-26

[15] Hong D, Zhou B, Zhang B, Ren H, Zhu L, Zheng G, Ge M, Ge J. Recent advances in the development of Egfr degraders: protacs and lytacs. Eur J Med Chem, 2022, 239 114533

[16] Hsu PC, Jablons DM, Yang CT, You L. Epidermal growth factor receptor (Egfr) pathway, yes-associated protein (Yap) and the regulation of programmed death-ligand 1 (Pd-l1) in non-small cell lung cancer (Nsclc). Int J Mol Sci, 2019

[17] Jiang J, Yuan Z, Sun Y, Bu Y, Li W, Fei Z. Ginsenoside Rg3 enhances the anti-proliferative activity of erlotinib in pancreatic cancer cell lines by downregulation of Egfr/Pi3k/Akt signaling pathway. Biomed Pharmacother, 2017, 96: 619-625

[18] Kharbanda A, Walter DM, Gudiel AA, Schek N, Feldser DM, Witze ES. Blocking Egfr palmitoylation suppresses Pi3k signaling and mutant Kras lung tumorigenesis. Sci Signal, 2020, 13 eaax2364

[19] Kim W-J, Lee M-Y, Kim J-H, Suk K, Lee W-H. Decursinol angelate blocks transmigration and inflammatory activation of cancer cells through inhibition of Pi3k, Erk and Nf-κb activation. Cancer Lett, 2010, 296: 35-42

[20] Li B, Ding CM, Li YX, Peng JC, Geng N, Qin WW. MicroRNA-145 inhibits migration and induces apoptosis in human non-small cell lung cancer cells through regulation of the Egfr/Pi3k/Akt signaling pathway. Oncol Rep, 2018, 40: 2944-2954

[21] Li Y, Xia J, Jiang N, Xian Y, Ju H, Wei Y, Zhang X. Corin protects H₂o₂-induced apoptosis through Pi3k/Akt and Nf-κb pathway in cardiomyocytes. Biomed Pharmacother, 2018, 97: 594-599

[22] Li Q, Li Z, Luo T, Shi H. Targeting the Pi3k/Akt/Mtor and Raf/Mek/Erk pathways for cancer therapy. Mol Biomed, 2022, 3 47

[23] Li S, Wang A, Wu Y, He S, Shuai W, Zhao M, Zhu Y, Hu X, Luo Y, Wang G. Targeted therapy for non-small-cell lung cancer: new insights into regulated cell death combined with immunotherapy. Immunol Rev, 2024, 321: 300-334

[24] Luo P, An Y, He J, Xing X, Zhang Q, Liu X, Chen Y, Yuan H, Chen J, Wong Y-K, Huang J, Gong Z, Du Q, Xiao W, Wang J. Icaritin with autophagy/mitophagy inhibitors synergistically enhances anticancer efficacy and apoptotic effects through Pink1/Parkin-mediated mitophagy in hepatocellular carcinoma. Cancer Lett, 2024, 587 216621

[25] Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, 2004, 350: 2129-2139

[26] Ma C, Wei S, Song Y. T790m and acquired resistance of Egfr Tki: a literature review of clinical reports. J Thorac Dis, 2011, 3: 10-18

[27] Matthews HK, Bertoli C, de Bruin RA. Cell cycle control in cancer. Nat Rev Mol Cell Biol, 2022, 23: 74-88

[28] Meng X, Jin Y, Yu Y, Bai J, Liu G, Zhu J, Zhao Y, Wang Z, Chen F, Lee K. Characterisation of fibronectin-mediated Fak signalling pathways in lung cancer cell migration and invasion. Br J Cancer, 2009, 101: 327-334

[29] Morohashi A, Satake M, Oshima Y, Yasumoto T. Absolute configuration at C45 in 45-hydroxyyessotoxin, a marine polyether toxin isolated from shellfish. Biosci Biotechnol Biochem, 2000, 64: 1761-1763

[30] Negrao MV, Araujo HA, Lamberti G, Cooper AJ, Akhave NS, Zhou T, Delasos L, Hicks JK, Aldea M, Minuti G. Comutations and Krasg12c inhibitor efficacy in advanced Nsclc. Cancer Discov, 2023, 13: 1556-1571

[31] Nishimura Y, Bereczky B, Ono M. The Egfr inhibitor gefitinib suppresses ligand-stimulated endocytosis of Egfr via the early/late endocytic pathway in non-small cell lung cancer cell lines. Histochem Cell Biol, 2007, 127: 541-553

[32] Niu M, Xu J, Liu Y, Li Y, He T, Ding L, He Y, Yi Y, Li F, Guo R. Fbxl2 counteracts Grp94 to destabilize Egfr and inhibit Egfr-driven Nsclc growth. Nat Commun, 2021, 12 5919

[33] Novikov NM, Zolotaryova SY, Gautreau AM, Denisov EV. Mutational drivers of cancer cell migration and invasion. Br J Cancer, 2021, 124: 102-114

[34] Padinharayil H, Varghese J, John MC, Rajanikant GK, Wilson CM, Al-Yozbaki M, Renu K, Dewanjee S, Sanyal R, Dey A. Non-small cell lung carcinoma (Nsclc): implications on molecular pathology and advances in early diagnostics and therapeutics. Genes Dis, 2023, 10: 960-989

[35] Pinilla-Macua I, Grassart A, Duvvuri U, Watkins SC, Sorkin A. Egf receptor signaling, phosphorylation, ubiquitylation and endocytosis in tumors in vivo. Elife, 2017, 6 e31993

[36] Qiao M, Jiang T, Liu X, Mao S, Zhou F, Li X, Zhao C, Chen X, Su C, Ren S. Immune checkpoint inhibitors in Egfr-mutated Nsclc: dusk or dawn?. J Thorac Oncol, 2021, 16: 1267-1288

[37] Saxton RA, Sabatini DM. Mtor signaling in growth, metabolism, and disease. Cell, 2017, 168: 960-976

[38] She Q-B, Solit DB, Ye Q, O’Reilly KE, Lobo J, Rosen N. The bad protein integrates survival signaling by Egfr/Mapk and Pi3k/Akt kinase pathways in Pten-deficient tumor cells. Cancer Cell, 2005, 8: 287-297

[39] Tubaro A, Dell'ovo V, Sosa S, Florio C. Yessotoxins: a toxicological overview. Toxicon, 2010, 56: 163-172

[40] Vidoni C, Ferraresi A, Secomandi E, Vallino L, Dhanasekaran DN, Isidoro C. Epigenetic targeting of autophagy for cancer prevention and treatment by natural compounds. Semin Cancer Biol, 2020, 66: 34-44

[41] Wang S, Tsui ST, Liu C, Song Y, Liu D. Egfr C797s mutation mediates resistance to third-generation inhibitors in T790m-positive non-small cell lung cancer. J Hematol Oncol, 2016, 9 59

[42] Wong RSY. Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res, 2011, 30 87

[43] Wu S, Luo M, To KK, Zhang J, Su C, Zhang H, An S, Wang F, Chen D, Fu L. Intercellular transfer of exosomal wild type Egfr triggers osimertinib resistance in non-small cell lung cancer. Mol Cancer, 2021, 20: 1-17

[44] Yan S, Zhang B, Feng J, Wu H, Duan N, Zhu Y, Zhao Y, Shen S, Zhang K, Wu W. Fgfc1 selectively inhibits erlotinib-resistant non-small cell lung cancer via elevation of Ros mediated by the Egfr/Pi3k/Akt/Mtor pathway. Front Pharmacol, 2022, 12 764699

[45] Zhang Y, Xiang C, Wang Y, Duan Y, Liu C, Jin Y, Zhang Y. Lncrna linc00152 knockdown had effects to suppress biological activity of lung cancer via Egfr/Pi3k/Akt pathway. Biomed Pharmacother, 2017, 94: 644-651

[46] Zhu Z, Li J, Shen S, Al-furas H, Li S, Tong Y, Li Y, Zeng Y, Feng Q, Chen K, Ma N, Zhou F, Zhang Z, Li Z, Pang J, Ding K, Xu F. Targeting Egfr degradation by autophagosome degraders. Eur J Med Chem, 2024, 270 116345

RIGHTS & PERMISSIONS

The Author(s), under exclusive licence to Ocean University of China